Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1970972-74-7
2. Danicamtiv [inn]
3. Danicamtiv [usan]
4. Myk-491
5. Sar440181
6. 7b2cs922hi
7. Myk491
8. Sar-440181
9. 1-piperidinecarboxamide, 4-((1r)-1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-3-isoxazolyl-
10. 4-[(1r)-1-[3-(difluoromethyl)-1-methylpyrazol-4-yl]sulfonyl-1-fluoroethyl]-n-(1,2-oxazol-3-yl)piperidine-1-carboxamide
11. Danicamtiv (usan/inn)
12. Danicamtiv (myk-491)
13. Unii-7b2cs922hi
14. Chembl4594304
15. Schembl17942536
16. Ex-a5015
17. S9948
18. Who 10942
19. Sar 440181;myk-491
20. Hy-109128
21. Cs-0086762
22. D11824
23. (r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide
24. 4-((1r)-1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(1,2-oxazol-3-yl)piperidine-1-carboxamide
| Molecular Weight | 435.4 g/mol |
|---|---|
| Molecular Formula | C16H20F3N5O4S |
| XLogP3 | 1.2 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 5 |
| Exact Mass | 435.11880980 g/mol |
| Monoisotopic Mass | 435.11880980 g/mol |
| Topological Polar Surface Area | 119 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 701 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
The Series B financing for Danicamtiv, targeting cardiac myosin, will advance heart health research and development.
Lead Product(s): Danicamtiv
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: MYK-491
Study Phase: Phase II/ Phase IIIProduct Type: Miscellaneous
Sponsor: Fidelity Management & Research Company
Deal Size: $254.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing October 14, 2025
Lead Product(s) : Danicamtiv
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Fidelity Management & Research Company
Deal Size : $254.0 million
Deal Type : Series B Financing
Kardigan Raises $254M Series B for Personalized Cardiovascular Medicines
Details : The Series B financing for Danicamtiv, targeting cardiac myosin, will advance heart health research and development.
Product Name : MYK-491
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 14, 2025
Details:
Danicamtiv is a small molecule drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Cardiomyopathy, Dilated.
Lead Product(s): Danicamtiv,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 07, 2025
Lead Product(s) : Danicamtiv,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Danicamtiv is a small molecule drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Cardiomyopathy, Dilated.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 07, 2025
Details:
Danicamtiv is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Danicamtiv,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 07, 2023
Lead Product(s) : Danicamtiv,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Danicamtiv is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 07, 2023
Details:
Danicamtiv is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Heart Failure, Systolic.
Lead Product(s): Danicamtiv,Midazolam
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 19, 2023
Lead Product(s) : Danicamtiv,Midazolam
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Danicamtiv is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Heart Failure, Systolic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 19, 2023
Details:
Danicamtiv is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Danicamtiv,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 10, 2023
Lead Product(s) : Danicamtiv,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Danicamtiv is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 10, 2023
Details:
Danicamtiv is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Danicamtiv,Itraconazole,Diltiazem
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 17, 2021
Lead Product(s) : Danicamtiv,Itraconazole,Diltiazem
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Danicamtiv is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 17, 2021
Details:
Danicamtiv is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cardiomyopathy, Dilated.
Lead Product(s): Danicamtiv,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 01, 2020
Lead Product(s) : Danicamtiv,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Danicamtiv is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cardiomyopathy, Dilated.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 01, 2020
Details:
First patient has been dosed in the company’s Phase 2 clinical trial of danicamtiv (formerly MYK-491) in people with primary dilated cardiomyopathy (DCM) thought to be caused by genetic mutations of the sarcomere.
Lead Product(s): Danicamtiv,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 09, 2020
Lead Product(s) : Danicamtiv,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : First patient has been dosed in the company’s Phase 2 clinical trial of danicamtiv (formerly MYK-491) in people with primary dilated cardiomyopathy (DCM) thought to be caused by genetic mutations of the sarcomere.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 09, 2020
Details:
Danicamtiv is MyoKardia’s lead activator candidate designed to increase the contractility of the heart with minimal or no effect on myocardial relaxation and compliance (diastolic function) by acting directly on the proteins in the heart muscle responsible for contraction.
Lead Product(s): Danicamtiv,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 19, 2020
Lead Product(s) : Danicamtiv,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MyoKardia Announces Danicamtiv Data Presentation at the European Society of Cardiology’s Virtual...
Details : Danicamtiv is MyoKardia’s lead activator candidate designed to increase the contractility of the heart with minimal or no effect on myocardial relaxation and compliance (diastolic function) by acting directly on the proteins in the heart muscle respons...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 19, 2020
Details:
MYK-491 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Heart Failure, Systolic.
Lead Product(s): Danicamtiv,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 27, 2018
Lead Product(s) : Danicamtiv,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MYK-491 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Heart Failure, Systolic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 27, 2018
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
29 Sep 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250929918876/en/Kardigan-Announces-Presentation-of-Positive-Phase-2a-Data-for-Danicamtiv-in-Patients-with-Dilated-Cardiomyopathy-at-HFSA-Annual-Scientific-Meeting-2025
09 Sep 2020
// PRESS RELEASE
https://myokardia.gcs-web.com/news-releases/news-release-details/myokardia-doses-first-patient-phase-2-clinical-trial-danicamtiv
ABOUT THIS PAGE
68
PharmaCompass offers a list of Danicamtiv API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Danicamtiv manufacturer or Danicamtiv supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Danicamtiv manufacturer or Danicamtiv supplier.
PharmaCompass also assists you with knowing the Danicamtiv API Price utilized in the formulation of products. Danicamtiv API Price is not always fixed or binding as the Danicamtiv Price is obtained through a variety of data sources. The Danicamtiv Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Danicamtiv manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Danicamtiv, including repackagers and relabelers. The FDA regulates Danicamtiv manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Danicamtiv API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Danicamtiv supplier is an individual or a company that provides Danicamtiv active pharmaceutical ingredient (API) or Danicamtiv finished formulations upon request. The Danicamtiv suppliers may include Danicamtiv API manufacturers, exporters, distributors and traders.
Danicamtiv Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Danicamtiv GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Danicamtiv GMP manufacturer or Danicamtiv GMP API supplier for your needs.
A Danicamtiv CoA (Certificate of Analysis) is a formal document that attests to Danicamtiv's compliance with Danicamtiv specifications and serves as a tool for batch-level quality control.
Danicamtiv CoA mostly includes findings from lab analyses of a specific batch. For each Danicamtiv CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Danicamtiv may be tested according to a variety of international standards, such as European Pharmacopoeia (Danicamtiv EP), Danicamtiv JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Danicamtiv USP).
Share 
